Clinical trials: Nerve Sheath Tumors
Sarcoma
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) scan and computated tomography (CT) scan, may help doctors predict a patient's response to treatment and may help plan the best treatment.
- Trial name
- NCT00346125
- Testing
- pegfilgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Vestibular Disorder, Vestibular Schwannoma
Measuring Vestibular Organ Function With Weak Alternating Current Stimulation
The goal of this clinical trial is to preliminarily evaluate the use of electrical stimulation in diagnosing disorders with the vestibular system.
- Conditions
- Vestibular Disorder, Vestibular Schwannoma, Vestibular Neuritis
- Trial name
- VESTI (NCT07267910)
- Testing
- Active transcranial electrical vestibular stimulation (Active EVS), Control measurement
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Aalto University
Dizziness
Vestibular Evaluation After Vestibular Schwannoma Treatment
Vestibular schwannoma is a benign tumor located on the vestibular nerve. Patient could present dizziness symptoms cause to the tumor, and at least after the treatment by gamaknife radiosurgery or microsurgery resection.
- Trial name
- EVTSVCGEC (NCT03670589)
- Testing
- Radiosurgery gammaknife, Microsurgery resection
- Where
- France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Grenoble
Liposarcoma, Malignant Peripheral Nerve Sheath Tumors
Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
The main purpose of this study is to establish a safe and tolerable dose combination (the "maximum tolerated dose") of selinexor and ixazomib when used together for the treatment of patients with certain types of advanced…
- Conditions
- Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma, Ewing Sarcoma
- Trial name
- NCT03880123
- Testing
- Selinexor, Ixazomib
- Where
- United States
- Sponsor
- Matthew Ingham
Neurofibromatosis 1
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1
Children with neurofibromatosis type 1 (NF1) commonly suffer from the effects of cognitive, behavioral, and motor impairments. At present there is no specific treatment for this NF1 complication.
- Trial name
- NF1NAC (NCT04481035)
- Testing
- N-acetylcysteine (NAC)
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Neurofibromatosis 2
Resiliency Training for Patients With NF2 Via Videoconferencing With Skype
The aim of this study is to determine, whether the 3RP is feasible, accepted and efficacious and durable when delivered via Skype to patients with neurofibromatosis type 2 (NF2) who are deaf or have severe hearing loss using…
- Trial name
- NCT02811718
- Testing
- Stress Management Group 1, Stress Management Group 2
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts General Hospital
Neurofibromatosis
Quality of Friendships in Children With Neurofibromatosis
The aim of this study is to determine if children with a higher disease severity have lower quality friendships than children who are less severely affected and children who are unaffected.
- Trial name
- NCT00508235
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Cutaneous Neurofibromas
First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas
The purpose of this study is to determine whether multiple cutaneous neurofibromas in patients with neurofibromatosis type 1 can be removed with an erbium-YAG-laser.
- Trial name
- NCT00921037
- Testing
- Erbium-YAG laser vaporization
- Where
- Austria
- Volunteers
- 12 people
- Sponsor
- Medical University of Vienna
Vestibular Schwannoma, Visual Impairment
Consequence of Unilateral Vestibular Loss on Visual Abilities
Unilateral vestibular lesions are frequent and disabling pathologies causing a set of oculomotor, postural and perceptual symptoms. These symptoms reduce over time according to a vestibular compensation.
- Conditions
- Vestibular Schwannoma, Visual Impairment, Vestibular Meniere Syndrome
- Trial name
- SVorthoptie (NCT03581331)
- Testing
- orthoptic balance
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Neurofibromatosis 1
Medical Treatment of "High-Risk" Neurofibromas
Patients with neurofibromatosis type 1 (NF1) commonly develop non-cancerous tumors called plexiform neurofibromas. These tumors can be defined as "high-risk" when they result in severe pain, physical disability, organ dysfunction…
- Trial name
- NCT00846430
- Testing
- Peg-Interferon alpha-2b, Celecoxib (Celebrex), Temozolomide (temodar)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Corewell Health West
Neoplasms, Nervous System Disease
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Background: Neurofibromatosis type II (NF2) is associated with tumors of the nerves, brain, and spinal cord. Most people with NF2 develop vestibular schwannomas, or tumors on the hearing and balance nerves.
- Conditions
- Neoplasms, Nervous System Disease, Vestibular Disease
- Trial name
- NCT01222728
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Neurofibromatosis 1, Social Skills
Pilot Randomized Control Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1
This is a pilot randomized control trial of the UCLA PEERS protocol delivered via Telehealth with teens with neurofibromatosis type 1 whose parents report that they have difficulty making and keeping friends.
- Trial name
- NCT04860362
- Testing
- PEERS
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Milwaukee
Ewing's Sarcoma, Rhabdomyosarcoma
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy
Filgrastim (granulocyte colony-stimulating factor), which is administered by daily subcutaneous injection after cytotoxic chemotherapy, shortens the duration of chemotherapy-induced neutropenia and lowers the risk of infection.
- Conditions
- Ewing's Sarcoma, Rhabdomyosarcoma, MPNST, Synovial Sarcoma
- Trial name
- NCT00004853
- Testing
- Filgrastim, Filgrastim-SD/01
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Wilms Tumor, Rhabdoid Tumor
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher…
- Conditions
- Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST
- Trial name
- NCT05985161
- Testing
- Selinexor
- Where
- 16 sites in United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neurofibromatosis Type 1
Gait in Young Children With NF1
The objective of this study is to develop office-based tools to quantify gait in young children with NF1 that reflect overall gross motor impairment and predict future gross motor difficulties.
- Trial name
- NCT07564622
- Volunteers
- 56 people
- Sponsor
- NYU Langone Health
Pediatric Solid Tumor, Germ Cell Tumor
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of…
- Conditions
- Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma
- Trial name
- NCT03618381
- Testing
- second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Seattle Children's Hospital
Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1)
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901).
- Trial name
- ReNeu (NCT03962543)
- Testing
- Mirdametinib (PD-0325901) oral capsule or dispersible tablet
- Where
- 43 sites in United States
- Volunteers
- 114 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Targeted Muscle Reinervation, Digital Amputation
Targeted Muscle Reinnervation in the Hand for the Managment of Symptomatic Neuroma Following Digit and Hand Amputations
Neuromas are a common complication after digital and hand amputations, resulting in significant pain, discomfort, and functional impairment.
- Conditions
- Targeted Muscle Reinervation, Digital Amputation, Neuroma
- Trial name
- NCT06923566
- Testing
- Targeted muscle reinnervation
- Where
- Egypt
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Neurofibromatosis Type 1, Legius Syndrome
Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)
This study may identify genes that predict the seriousness of neurofibromatosis type 1 (NF1). Finding these genes may explain why some people with NF1 have more medical problems than others.
- Trial name
- NCT00111384
- Where
- United States
- Volunteers
- 313 people
- Sponsor
- National Cancer Institute (NCI)
Neurofibromatosis 1
iCanCope With NF: Innovating an Efficacious Digital Self-management and Transitional Care Program for Adolescents With Neurofibromatosis
Neurofibromatosis Type 1 (NF1) often significantly impairs the mental health, social life, self-esteem, and quality of life of adolescent patients. These impacts can be made worse with the experience of NF1-related pain.
- Trial name
- NCT07077408
- Testing
- iCanCope-NF Youth app, iCanCope-NF Youth app + CM
- Volunteers
- 60 people
- Sponsor
- The Hospital for Sick Children